Undisclosed CAR-T Program
Hematological Malignancies
Key Facts
About OBiO Technology
Chinese biotech developing CRISPR-based gene and cell therapies for oncology and genetic disorders.
View full company profileAbout Cellergy Pharma
Cellergy Pharma is an innovative, private biotech leveraging CAR T cell technology to address severe allergic diseases, a novel and significant expansion of this therapeutic modality. The company is in the pre-clinical or early research stage, focusing on large, underserved markets such as severe allergic asthma and food allergies. As a pre-revenue entity, its success hinges on validating its platform in non-oncological settings, securing substantial funding, and navigating the complex regulatory pathway for a first-in-class cell therapy in allergy.
View full company profileAbout Cellergy Pharma
Cellergy Pharma is an innovative, private biotech leveraging CAR T cell technology to address severe allergic diseases, a novel and significant expansion of this therapeutic modality. The company is in the pre-clinical or early research stage, focusing on large, underserved markets such as severe allergic asthma and food allergies. As a pre-revenue entity, its success hinges on validating its platform in non-oncological settings, securing substantial funding, and navigating the complex regulatory pathway for a first-in-class cell therapy in allergy.
View full company profileTherapeutic Areas
Other Hematological Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| NST-201 (estimated) | Novastage Pharmaceuticals | Preclinical/IND-enabling |
| TYK-201 | TYK Medicines | Preclinical |
| TNB-655 | Tenacia Biotechnology | Preclinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| PS-102 | Perimeter Systems, Inc. | Preclinical |
| JaxBio Hematology Cancer Test | JaxBio | Preclinical |
| YZY-002 | YZY Biopharma | Phase 1 |